Xilio Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Xilio Therapeutics has a total shareholder equity of $21.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $74.7M and $53.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$61.26m |
| Equity | US$20.97m |
| Total liabilities | US$53.68m |
| Total assets | US$74.66m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: XLO's short term assets ($63.3M) exceed its short term liabilities ($38.0M).
Long Term Liabilities: XLO's short term assets ($63.3M) exceed its long term liabilities ($15.7M).
Debt to Equity History and Analysis
Debt Level: XLO is debt free.
Reducing Debt: XLO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XLO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: XLO has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 0.5% each year.